Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Csilla Leveleki is active.

Publication


Featured researches published by Csilla Leveleki.


Progress in Neuro-psychopharmacology & Biological Psychiatry | 2003

The effect of social factors on the anxiolytic efficacy of buspirone in male rats, male mice, and men

Eszter Majercsik; József Haller; Csilla Leveleki; Johanna Baranyi; József Halász; R.J. Rodgers

Earlier findings suggest that housing conditions in laboratory animals and life events in humans influence the efficacy of anxiolytic drugs. Here we report on the impact of social isolation on buspirone efficacy in male mice and rats as assessed by the elevated plus-maze. In addition, the impact of social support on buspirone efficacy was assessed in male patients. When administered 30 min before testing and irrespective of housing conditions, buspirone significantly suppressed locomotor activity both in mice (6 mg/kg) and rats (10 mg/kg) and, as such, other behavioral changes observed at this time point must be seen as behaviorally nonselective. However, these locomotor disruptive effects of buspirone were not evident in either species at longer injection-test intervals (2 and 4 h). When given 2 h prior to testing, a low (3 mg/kg) but not high (10 mg/kg) dose of buspirone increased the frequency of open arm exploration in rats (but not mice) irrespective of housing conditions. At the longest injection-test interval used (4 h), buspirone increased the duration of open arm exploration in individually housed, but not group-housed, rats. Similar, though somewhat less robust, effects were observed in male mice at this time. In a double-blind placebo-controlled study with male patients, chronic buspirone treatment (3 x 10 mg daily for 6 weeks) produced a highly significant reduction in scores on the Hamilton Rating Scale for Anxiety (HAM-A). Multiple regression analysis of social support received by patients indicated that the support of nonrelatives (but not of family or other relatives) was a strong positive predictor of buspirone efficacy. Taken together, our data support the hypothesis that social conditions affect the anxiolytic efficacy of buspirone. Results are discussed in relation to differences in the social organization of the three species investigated.


Psychopharmacology | 2001

The effect of glucocorticoids on the anxiolytic efficacy of buspirone

József Haller; Csilla Leveleki; József Halász; Johanna Baranyi; Gábor B. Makara

Abstract. Rationale: The serotonergic system and the hypothalamus–hypophysis–adrenocortical axis reciprocally influence each other. Therefore, the interaction between stress and serotonergic anxiolytics should be of major concern for both laboratory investigations and clinical treatment. Objectives: We have studied the effects of the serotonergic anxiolytic buspirone in rats in which basal levels of glucocorticoids were low and stable, while acute stress reactions were inhibited or exogenously induced. Methods: Rats were adrenalectomised. Subcutaneous corticosterone pellets maintained basal glucocorticoid concentrations while acute changes were mimicked by corticosterone injections. Anxiety was assessed by the social interaction test. Temporal changes were evaluated by submitting rats to the same manipulations three times at two-day intervals. Results: Buspirone applied to animals with stable and low plasma glucocorticoid concentrations induced a dramatic increase in social interactions. A slight locomotor suppressive effect was also noticed. The effects of buspirone proved to be stable over time in these animals. Acute treatment with corticosterone doubled the locomotor suppressive effects of buspirone and reversed its anxiolytic effects: the buspirone–corticosterone combination was anxiogenic after the first application. During the second and third treatment, the impact of corticosterone on buspirone efficacy gradually decreased, but the combined treatment remained about half as effective in reducing anxiety as buspirone alone.


Psychopharmacology | 2008

Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: Effects of GYKI 52466 and its novel analogues

Gábor Kapus; Istvan Gacsalyi; Miklos Vegh; Hajnalka Kompagne; Entire Hegedüs; Csilla Leveleki; L. Hársing; Jozsef Barkoczy; Andras Bilkei-Gorzo; György Lévay


Archive | 2005

3-(((4-phenyl)-piperazine-1-yl)-alkyl)-3-alkyl-1, 3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders

Balázs Volk; Jozsef Barkoczy; Gyula Simig; Tibor Mezei; Dezsofi Rita Kapillerne; Endréné Flórián; Istvan Gacsalyi; Katalin Pallagi; Gabor Gigler; Gyoergy Levay; Krisztina Moricz; Csilla Leveleki; Nora Sziray; Gábor Szénási; Andras Egyed; Laszlo Gabor Harsing


Archive | 2002

Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same

Jozsef Barkoczy; Andras Egyed; Istvan Gacsalyi; Laszlo Gabor Harsing; Hajnalka Kompagne; Peter Kotay Nagy; György Lévay; Csilla Leveleki; Bernadett Marko; Anikó Kovács; Eva Schmidt; Gyula Simig; Gábor Szénási; Janos Wellmann


Archive | 2005

Piperazine derivatives of alkyl oxindoles

Balázs Volk; Jozsef Barkoczy; Gyula Simig; Tibor Mezei; Dezsofi Rita Kapillerne; Istvan Gacsalyi; Katalin Pallagi; Gabor Gigler; Gyoergy Levay; Krisztina Moricz; Csilla Leveleki; Nora Sziray; Gábor Szénási; Andras Egyed; Laszlo Gabor Harsing


Archive | 2007

Pyridine Derivatives of Alkyl Oxindoles as 5-Ht7 Receptor Active Agents

Balázs Volk; Jozsef Barkoczy; Gyula Simig; Tibor Mezei; Dezsofi Rita Kapillerne; Istvan Gacsalyi; Katalin Pallagi; Gabor Gigler; György Lévay; Krisztina Moricz; Csilla Leveleki; Nora Sziray; Gábor Szénási; Andras Egyed; Laszlo Gabor Harsing


Archive | 2005

Piperazine Derivatives of Dialkyl Oxindoles

Balázs Volk; Jozsef Barkoczy; Gyula Simig; Tibor Mezei; Rita Kapillerne Dezsofi; Endréné Flórián; Istvan Gacsalyi; Katalin Pallagi; Gabor Gigler; György Lévay; Krisztina Moricz; Csilla Leveleki; Nora Sziray; Gabor Szenasl; Andras Egyed; Laszlo Gabor Harsing


Archive | 2003

Substituted alkyl-pyridazinones for the treatment of memory and learning malfunctions

Gyoergy Levay; Istvan Gacsalyi; Bernadett Marko; Eva Schmidt; Andras Egyed; Hajnalka Kompagne; Csilla Leveleki; Kovacs Aniko Miklosne; Gábor Szénási; Janos Wellmann; Laszlo Gabor Harsing; Jozsef Barkoczy; Gyula Simig; Nagy Peter Kotay


Archive | 2009

3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE

Márta Porcs-Makkay; Gyula Lukács; Gábor Kapus; Istvan Gacsalyi; Gyula Simig; Gyoergy Levay; Tibor Mezei; Miklos Vegh; Szabolcs Kertesz; Jozsef Barkoczy; Csilla Leveleki; Laszlo Gabor Harsing

Collaboration


Dive into the Csilla Leveleki's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge